Marrone Bio (MBII) Receives a Buy from Lake Street

In a report released today, Ben Klieve from Lake Street reiterated a Buy rating on Marrone Bio (MBIIResearch Report), with a price target of $1.30. The company’s shares closed last Thursday at $1.05.

According to, Klieve is ranked #403 out of 7913 analysts.

Marrone Bio has an analyst consensus of Moderate Buy, with a price target consensus of $1.88.

See today’s best-performing stocks on TipRanks >>

The company has a one-year high of $2.56 and a one-year low of $0.55. Currently, Marrone Bio has an average volume of 847.3K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Marrone Bio Innovations, Inc. engages in the provision of bio-based pest management and plant health products for the agricultural and water treatment markets. Its brand includes regalia, bio-tam, grandevo, venerate and majestene. The company was founded by Pamela G. Marrone on June 15, 2006 and is headquartered in Davis, CA.

Read More on MBII:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More